[
  {
    "ts": null,
    "headline": "Eli Lilly Confirms Plan To Buy Ventyx Biosciences In $1.2 Billion Deal",
    "summary": "Eli Lilly confirmed its $1.2 billion plan late Wednesday to acquire Ventyx Biosciences. Ventyx stock ran up nearly 40% during regular trades.",
    "url": "https://finnhub.io/api/news?id=08c8fb1249774368540b69107c5d7c76473df9b4ee80ecaa242b466989723cf1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767827297,
      "headline": "Eli Lilly Confirms Plan To Buy Ventyx Biosciences In $1.2 Billion Deal",
      "id": 138033028,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly confirmed its $1.2 billion plan late Wednesday to acquire Ventyx Biosciences. Ventyx stock ran up nearly 40% during regular trades.",
      "url": "https://finnhub.io/api/news?id=08c8fb1249774368540b69107c5d7c76473df9b4ee80ecaa242b466989723cf1"
    }
  },
  {
    "ts": null,
    "headline": "Lilly moves beyond blockbuster obesity drugs with $1.2 billion Ventyx buy",
    "summary": "By Puyaan Singh Jan 7 (Reuters) - Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, marking the Zepbound maker's latest push to",
    "url": "https://finnhub.io/api/news?id=06386dce7b7bf971fe4d13a0cc39e1ff0ae5fca14c17387afa5e6c45143ab96c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767824332,
      "headline": "Lilly moves beyond blockbuster obesity drugs with $1.2 billion Ventyx buy",
      "id": 138033029,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "By Puyaan Singh Jan 7 (Reuters) - Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, marking the Zepbound maker's latest push to",
      "url": "https://finnhub.io/api/news?id=06386dce7b7bf971fe4d13a0cc39e1ff0ae5fca14c17387afa5e6c45143ab96c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, IBD Stock Of The Day, Offers Two Entries On Rumored Buyout Rally",
    "summary": "Eli Lilly is Wednesday's IBD Stock Of The Day. Shares are breaking above a pair of bases as rumors swirl about a potential Ventyx buyout.",
    "url": "https://finnhub.io/api/news?id=d9140c6702c44be0c1a56c78d6fbe790532a5789bd9d2033f19e6b4606b00495",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767822567,
      "headline": "Eli Lilly, IBD Stock Of The Day, Offers Two Entries On Rumored Buyout Rally",
      "id": 138033030,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly is Wednesday's IBD Stock Of The Day. Shares are breaking above a pair of bases as rumors swirl about a potential Ventyx buyout.",
      "url": "https://finnhub.io/api/news?id=d9140c6702c44be0c1a56c78d6fbe790532a5789bd9d2033f19e6b4606b00495"
    }
  },
  {
    "ts": null,
    "headline": "3 Drug Stocks to Buy at a Discount",
    "summary": "The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.",
    "url": "https://finnhub.io/api/news?id=9fcdcc39ce0addd277b2951b739d1aac0fe758a8e69a9b299ea726657eeba350",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767820800,
      "headline": "3 Drug Stocks to Buy at a Discount",
      "id": 138033031,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.",
      "url": "https://finnhub.io/api/news?id=9fcdcc39ce0addd277b2951b739d1aac0fe758a8e69a9b299ea726657eeba350"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases",
    "summary": "Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases, today announced entry into a definitive agreement for Lilly to acquire Ventyx.",
    "url": "https://finnhub.io/api/news?id=e8f69b7aa0b0d649aac7e07672e3e00a1efc8c19cb154aabfc3fffb4980179ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767820620,
      "headline": "Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases",
      "id": 138033032,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases, today announced entry into a definitive agreement for Lilly to acquire Ventyx.",
      "url": "https://finnhub.io/api/news?id=e8f69b7aa0b0d649aac7e07672e3e00a1efc8c19cb154aabfc3fffb4980179ed"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Gain Late Afternoon",
    "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 0.7% and th",
    "url": "https://finnhub.io/api/news?id=f7d1cdb09ab9ee10265c577baf474f32a19fadf1143eff3e933cb71089d94a29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767818827,
      "headline": "Sector Update: Health Care Stocks Gain Late Afternoon",
      "id": 138033033,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 0.7% and th",
      "url": "https://finnhub.io/api/news?id=f7d1cdb09ab9ee10265c577baf474f32a19fadf1143eff3e933cb71089d94a29"
    }
  },
  {
    "ts": null,
    "headline": "InduPro Therapeutics Announces Strategic Collaboration with Lilly to Develop First-in-Class Bispecific/Multispecific Oncology Therapeutics Using InduPro’s Proximity-Guided Platform",
    "summary": "SEATTLE & CAMBRIDGE, Mass., January 07, 2026--InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced a global strategic collaboration and licensing agreement, and equity investment, with Eli Lilly and Company (\"Lilly\") to discover novel oncology treatments using InduPro’s proximity-guided platform.",
    "url": "https://finnhub.io/api/news?id=1e5ab5c00d43fc2c993519cdea61a2ba7b805b36e5e9ea80124dc888c22537d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767808800,
      "headline": "InduPro Therapeutics Announces Strategic Collaboration with Lilly to Develop First-in-Class Bispecific/Multispecific Oncology Therapeutics Using InduPro’s Proximity-Guided Platform",
      "id": 138033034,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "SEATTLE & CAMBRIDGE, Mass., January 07, 2026--InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced a global strategic collaboration and licensing agreement, and equity investment, with Eli Lilly and Company (\"Lilly\") to discover novel oncology treatments using InduPro’s proximity-guided platform.",
      "url": "https://finnhub.io/api/news?id=1e5ab5c00d43fc2c993519cdea61a2ba7b805b36e5e9ea80124dc888c22537d4"
    }
  },
  {
    "ts": null,
    "headline": "Biotechnology Instruments Market Projected to Reach US$ 141.70 Billion by 2035 | Astute Analytica",
    "summary": "The market offers explosive potential as biology transitions to factory-scale production. Anchored by the USD 100 genome and high-margin consumables, the sector promises sustained scalability. Massive infrastructure investments, like Eli Lilly’s USD 4.5 billion campus, confirm a lucrative, long-term trajectory.Chicago, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The global biotechnology instruments market size stood at USD 92.12 billion in 2025 and is expected to reach USD 141.70 billion by 2035 with a 4.",
    "url": "https://finnhub.io/api/news?id=2c6df170734f8e8f3423edb1075eb7203f0452c82d201cda5c037991f25d1254",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767803400,
      "headline": "Biotechnology Instruments Market Projected to Reach US$ 141.70 Billion by 2035 | Astute Analytica",
      "id": 138033035,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The market offers explosive potential as biology transitions to factory-scale production. Anchored by the USD 100 genome and high-margin consumables, the sector promises sustained scalability. Massive infrastructure investments, like Eli Lilly’s USD 4.5 billion campus, confirm a lucrative, long-term trajectory.Chicago, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The global biotechnology instruments market size stood at USD 92.12 billion in 2025 and is expected to reach USD 141.70 billion by 2035 with a 4.",
      "url": "https://finnhub.io/api/news?id=2c6df170734f8e8f3423edb1075eb7203f0452c82d201cda5c037991f25d1254"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Stock Is Up, What You Need To Know",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.3% in the morning session after the company announced a partnership to develop a new oral obesity drug and was reported to be in advanced talks to acquire Ventyx Biosciences for over $1 billion.",
    "url": "https://finnhub.io/api/news?id=288db25f53b4b34b024f56e351dd2bd0feb27fe6df5a46928145aa92797fede9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767802888,
      "headline": "Eli Lilly (LLY) Stock Is Up, What You Need To Know",
      "id": 138027899,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.3% in the morning session after the company announced a partnership to develop a new oral obesity drug and was reported to be in advanced talks to acquire Ventyx Biosciences for over $1 billion.",
      "url": "https://finnhub.io/api/news?id=288db25f53b4b34b024f56e351dd2bd0feb27fe6df5a46928145aa92797fede9"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Wednesday: Strategy, Applied Digital, Chevron",
    "summary": "↗️ Strategy (MSTR): Shares of the bitcoin-accumulation company climbed 5% premarket after index provider MSCI said it won't exclude crypto treasury companies from its indexes. ↘️ Newmont (NEM), Freeport-McMoRan (FCX), Antofagasta (UK: ANTO): Global mining stocks came under pressure as a rally in precious and industrial metals stalled.",
    "url": "https://finnhub.io/api/news?id=3947d35a6352ed13bfa6be4bd6f31b6f4f548ee4bafa02a4e810c013d9669c0a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767778829,
      "headline": "Stocks to Watch Wednesday: Strategy, Applied Digital, Chevron",
      "id": 138025847,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "↗️ Strategy (MSTR): Shares of the bitcoin-accumulation company climbed 5% premarket after index provider MSCI said it won't exclude crypto treasury companies from its indexes. ↘️ Newmont (NEM), Freeport-McMoRan (FCX), Antofagasta (UK: ANTO): Global mining stocks came under pressure as a rally in precious and industrial metals stalled.",
      "url": "https://finnhub.io/api/news?id=3947d35a6352ed13bfa6be4bd6f31b6f4f548ee4bafa02a4e810c013d9669c0a"
    }
  },
  {
    "ts": null,
    "headline": "Investors Digest Labor Market Data as US Equity Futures Tread Water Pre-Bell",
    "summary": "US equity futures were flat ahead of Wednesday's opening bell as traders digested labor market data.",
    "url": "https://finnhub.io/api/news?id=e73207716eb18867e63a78ac0d358a900a6b9c9fcfdee9b126eadb1c0f43bdd6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767795090,
      "headline": "Investors Digest Labor Market Data as US Equity Futures Tread Water Pre-Bell",
      "id": 138027070,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US equity futures were flat ahead of Wednesday's opening bell as traders digested labor market data.",
      "url": "https://finnhub.io/api/news?id=e73207716eb18867e63a78ac0d358a900a6b9c9fcfdee9b126eadb1c0f43bdd6"
    }
  },
  {
    "ts": null,
    "headline": "How The Narrative Around Nektar Therapeutics (NKTR) Is Shifting With Rezpeg Data And Litigation Risks",
    "summary": "Nektar Therapeutics just saw its fair value model refreshed, with the headline number holding steady at US$114.43 per share even as the long term revenue growth assumption for Rezpeg edged to a 10.83% decline. This reflects a slightly less negative view of future sales potential tied to upcoming clinical data and Alopecia Areata optionality. Behind that small shift is a tug of war in Street research between bullish views that Rezpeg’s clinical profile could support higher long term revenue...",
    "url": "https://finnhub.io/api/news?id=e75665475d6273f5bd0da13c81f66514d6e71ccde3b1ecb8c6f7b55c6b0e4d2b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767791522,
      "headline": "How The Narrative Around Nektar Therapeutics (NKTR) Is Shifting With Rezpeg Data And Litigation Risks",
      "id": 138027071,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Nektar Therapeutics just saw its fair value model refreshed, with the headline number holding steady at US$114.43 per share even as the long term revenue growth assumption for Rezpeg edged to a 10.83% decline. This reflects a slightly less negative view of future sales potential tied to upcoming clinical data and Alopecia Areata optionality. Behind that small shift is a tug of war in Street research between bullish views that Rezpeg’s clinical profile could support higher long term revenue...",
      "url": "https://finnhub.io/api/news?id=e75665475d6273f5bd0da13c81f66514d6e71ccde3b1ecb8c6f7b55c6b0e4d2b"
    }
  },
  {
    "ts": null,
    "headline": "Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference",
    "summary": "SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D., president and chief executive officer of Recludix, will present an overview of the company’s progress at the Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The company’s presentation will be on Thursday, January 15, 2026, at 9:30 a.m. Pacific Time. A",
    "url": "https://finnhub.io/api/news?id=98458baac9308b601dd54aed96efa1fdc0052d02958296270deb512738016f41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767790800,
      "headline": "Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference",
      "id": 138027073,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D., president and chief executive officer of Recludix, will present an overview of the company’s progress at the Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The company’s presentation will be on Thursday, January 15, 2026, at 9:30 a.m. Pacific Time. A",
      "url": "https://finnhub.io/api/news?id=98458baac9308b601dd54aed96efa1fdc0052d02958296270deb512738016f41"
    }
  },
  {
    "ts": null,
    "headline": "BigHat Biosciences Partners With Lilly to Advance Machine-Learning-Enabled Biologics Discovery Through Lilly TuneLab",
    "summary": "SAN MATEO, Calif., January 07, 2026--BigHat Biosciences, a protein therapeutics company that combines state-of-the-art AI models with a high-speed automated wet lab, today announced a collaboration with Eli Lilly and Company (Lilly) focused on advancing machine-learning-enabled biologics discovery through Lilly TuneLab. This project expands BigHat’s relationship with Lilly, which includes a previously disclosed collaboration focused on the discovery and engineering of next-generation antibody th",
    "url": "https://finnhub.io/api/news?id=fc76021b9f012a216ba28d78d13792b608f55bb1413ee937789adcba71a7c46b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767790800,
      "headline": "BigHat Biosciences Partners With Lilly to Advance Machine-Learning-Enabled Biologics Discovery Through Lilly TuneLab",
      "id": 138027072,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "SAN MATEO, Calif., January 07, 2026--BigHat Biosciences, a protein therapeutics company that combines state-of-the-art AI models with a high-speed automated wet lab, today announced a collaboration with Eli Lilly and Company (Lilly) focused on advancing machine-learning-enabled biologics discovery through Lilly TuneLab. This project expands BigHat’s relationship with Lilly, which includes a previously disclosed collaboration focused on the discovery and engineering of next-generation antibody th",
      "url": "https://finnhub.io/api/news?id=fc76021b9f012a216ba28d78d13792b608f55bb1413ee937789adcba71a7c46b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus",
    "summary": "Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.",
    "url": "https://finnhub.io/api/news?id=199a4981bfcf78dc28d138b7bdca0a880f30712d5be992890858ec90fc43ecc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767790174,
      "headline": "Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus",
      "id": 138027074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.",
      "url": "https://finnhub.io/api/news?id=199a4981bfcf78dc28d138b7bdca0a880f30712d5be992890858ec90fc43ecc5"
    }
  },
  {
    "ts": null,
    "headline": "Arrowhead’s RNAi-based obesity drug combo shows benefit in Phase I/IIa trial",
    "summary": "Arrowhead’s stock rose 6% on market open after the announcement though continued to rise throughout the day.",
    "url": "https://finnhub.io/api/news?id=1afad823850dae5c82df73444a8a2809fe7f91e5f449417f0b147fd109ffbcd7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767788560,
      "headline": "Arrowhead’s RNAi-based obesity drug combo shows benefit in Phase I/IIa trial",
      "id": 138027075,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Arrowhead’s stock rose 6% on market open after the announcement though continued to rise throughout the day.",
      "url": "https://finnhub.io/api/news?id=1afad823850dae5c82df73444a8a2809fe7f91e5f449417f0b147fd109ffbcd7"
    }
  },
  {
    "ts": null,
    "headline": "Stocks making the biggest moves midday: Deckers Outdoor, Amgen, Western Digital, Ventyx Biosciences & more",
    "summary": "Check out some of the biggest movers in midday trading.",
    "url": "https://finnhub.io/api/news?id=c89cdc3e4b6bb7beb5c966a3d602f82319b80feab433f7d34df14831de8c38ac",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767788408,
      "headline": "Stocks making the biggest moves midday: Deckers Outdoor, Amgen, Western Digital, Ventyx Biosciences & more",
      "id": 138028002,
      "image": "https://image.cnbcfm.com/api/v1/image/107419799-1716556047925-gettyimages-1246717795-porzycki-polandsn230201_npl09.jpeg?v=1767805826&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Check out some of the biggest movers in midday trading.",
      "url": "https://finnhub.io/api/news?id=c89cdc3e4b6bb7beb5c966a3d602f82319b80feab433f7d34df14831de8c38ac"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Nears Deal to Buy Ventyx Biosciences for Over $1 Billion",
    "summary": "Biotech acquisition would expand Lilly's pipeline in inflammatory and metabolic diseases",
    "url": "https://finnhub.io/api/news?id=4561c06a332b0f37ad21b8d1b787b2d0bbd622004e5f4e6da6d641e5a5117d26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767788014,
      "headline": "Eli Lilly Nears Deal to Buy Ventyx Biosciences for Over $1 Billion",
      "id": 138027077,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Biotech acquisition would expand Lilly's pipeline in inflammatory and metabolic diseases",
      "url": "https://finnhub.io/api/news?id=4561c06a332b0f37ad21b8d1b787b2d0bbd622004e5f4e6da6d641e5a5117d26"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly (LLY) Still Sensibly Priced After Its Strong Multi Year Share Price Run",
    "summary": "If you are wondering whether Eli Lilly's share price still makes sense after a long run up, or if the stock is starting to look stretched, this article walks through what the current market price could be implying about value. The stock most recently closed at US$1,064.04, with a 1.5% decline over the last 7 days, a 5.3% gain over the last 30 days, a 1.5% decline year to date, a 38.6% return over 1 year and a very large 5-year return that is well above 7x. Recent coverage of Eli Lilly has...",
    "url": "https://finnhub.io/api/news?id=bde4501200d161468d7e3dad449b5818d12752ebebb5a22005b26a6d3ecacd5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767788000,
      "headline": "Is Eli Lilly (LLY) Still Sensibly Priced After Its Strong Multi Year Share Price Run",
      "id": 138027078,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "If you are wondering whether Eli Lilly's share price still makes sense after a long run up, or if the stock is starting to look stretched, this article walks through what the current market price could be implying about value. The stock most recently closed at US$1,064.04, with a 1.5% decline over the last 7 days, a 5.3% gain over the last 30 days, a 1.5% decline year to date, a 38.6% return over 1 year and a very large 5-year return that is well above 7x. Recent coverage of Eli Lilly has...",
      "url": "https://finnhub.io/api/news?id=bde4501200d161468d7e3dad449b5818d12752ebebb5a22005b26a6d3ecacd5b"
    }
  },
  {
    "ts": null,
    "headline": "Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio",
    "summary": "Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced an oversubscribed $76 million Series B financing co-led by Amplitude Ventures and ICG, with participation from new investors Longwood Fund, Asahi Kasei Pharma Ventures, Alexandria Real Estate Trust (ARE), and existing Series A investors. Joining the Mediar board from Amplitude Ventures is Bharat Srinivasa, PhD, and from ICG is Allan Marchington, PhD. Pro",
    "url": "https://finnhub.io/api/news?id=dbf40ede4d07e85c05281c4aeefbde3e2dd559658dc59775a7efef90583f060f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767787200,
      "headline": "Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio",
      "id": 138025811,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced an oversubscribed $76 million Series B financing co-led by Amplitude Ventures and ICG, with participation from new investors Longwood Fund, Asahi Kasei Pharma Ventures, Alexandria Real Estate Trust (ARE), and existing Series A investors. Joining the Mediar board from Amplitude Ventures is Bharat Srinivasa, PhD, and from ICG is Allan Marchington, PhD. Pro",
      "url": "https://finnhub.io/api/news?id=dbf40ede4d07e85c05281c4aeefbde3e2dd559658dc59775a7efef90583f060f"
    }
  },
  {
    "ts": null,
    "headline": "Trending tickers: Micron, Sandisk Corporation, Ventyx Biosciences, BP and Reckitt",
    "summary": "The latest investor updates on stocks that are trending on Wednesday.",
    "url": "https://finnhub.io/api/news?id=fb6087532eb9aba14229ec0545afea06501db0b9a8ddf28710cf4c799fc89f43",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767783028,
      "headline": "Trending tickers: Micron, Sandisk Corporation, Ventyx Biosciences, BP and Reckitt",
      "id": 138025717,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The latest investor updates on stocks that are trending on Wednesday.",
      "url": "https://finnhub.io/api/news?id=fb6087532eb9aba14229ec0545afea06501db0b9a8ddf28710cf4c799fc89f43"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer's top 10 things to watch in the stock market Wednesday",
    "summary": "The stock market was little changed this morning after the S&P 500 hit records highs Tuesday.",
    "url": "https://finnhub.io/api/news?id=a57b975de029806c09eb01c4b7ec39385868263fc9dfb7e3d6ee1aa602c63b5b",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767777423,
      "headline": "Jim Cramer's top 10 things to watch in the stock market Wednesday",
      "id": 138027947,
      "image": "https://image.cnbcfm.com/api/v1/image/107200469-1677528554271-NUP_200782_00155.jpg?v=1721682202&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The stock market was little changed this morning after the S&P 500 hit records highs Tuesday.",
      "url": "https://finnhub.io/api/news?id=a57b975de029806c09eb01c4b7ec39385868263fc9dfb7e3d6ee1aa602c63b5b"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma race to snap up biotech assets as $170 billion patent cliff looms",
    "summary": "Companies are facing a situation where they need to fill their pipelines, but also navigate a competitive environment for the best assets.",
    "url": "https://finnhub.io/api/news?id=a0c504f9e512dfd1f9c4c0c403aa8efad6e2dd4ab308b1791cfebe567d1454ed",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767753071,
      "headline": "Big Pharma race to snap up biotech assets as $170 billion patent cliff looms",
      "id": 138028004,
      "image": "https://image.cnbcfm.com/api/v1/image/108248856-1767718931887-gettyimages-1417392226-_x3m1126.jpeg?v=1767718937&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Companies are facing a situation where they need to fill their pipelines, but also navigate a competitive environment for the best assets.",
      "url": "https://finnhub.io/api/news?id=a0c504f9e512dfd1f9c4c0c403aa8efad6e2dd4ab308b1791cfebe567d1454ed"
    }
  },
  {
    "ts": null,
    "headline": "Best Peptides for Weight Loss 2026: Oral Wegovy Launch Expands GLP-1 Format Options as Telehealth Platforms Compare FDA-Approved vs Compounded Semaglutide Access",
    "summary": "Following Oral Wegovy Introduction, Consumer Analysis Examines Injectable vs Oral Semaglutide Pricing, Compounded Tirzepatide Access Through Direct Meds, and Three-Entity Telehealth Platform StructureHOUSTON, TX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Medical decisions about prescription weight-management treatments are appropriately made with a qualified clinician who can evaluate individual risks and eligibility.",
    "url": "https://finnhub.io/api/news?id=f1527a18d00dd22d099eb71c6376ac634ed725c1f1587adc8f36c7aaa1cc8bc0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767751800,
      "headline": "Best Peptides for Weight Loss 2026: Oral Wegovy Launch Expands GLP-1 Format Options as Telehealth Platforms Compare FDA-Approved vs Compounded Semaglutide Access",
      "id": 138022691,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Following Oral Wegovy Introduction, Consumer Analysis Examines Injectable vs Oral Semaglutide Pricing, Compounded Tirzepatide Access Through Direct Meds, and Three-Entity Telehealth Platform StructureHOUSTON, TX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Medical decisions about prescription weight-management treatments are appropriately made with a qualified clinician who can evaluate individual risks and eligibility.",
      "url": "https://finnhub.io/api/news?id=f1527a18d00dd22d099eb71c6376ac634ed725c1f1587adc8f36c7aaa1cc8bc0"
    }
  },
  {
    "ts": null,
    "headline": "Warning: This Skyrocketing Stock Has a Hidden Risk",
    "summary": "Novo Nordisk's new GLP-1 pill highlights the risk that Eli Lilly faces, as investors reward it for being at the forefront of the weight loss market.",
    "url": "https://finnhub.io/api/news?id=53b631d9f49304842a75ad5058b06a2fb489a4538c26c1eb02e3f1c426413baa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767750600,
      "headline": "Warning: This Skyrocketing Stock Has a Hidden Risk",
      "id": 138022692,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk's new GLP-1 pill highlights the risk that Eli Lilly faces, as investors reward it for being at the forefront of the weight loss market.",
      "url": "https://finnhub.io/api/news?id=53b631d9f49304842a75ad5058b06a2fb489a4538c26c1eb02e3f1c426413baa"
    }
  }
]